Biotech Values

[DewDiligence]

OPGN IPOs 3.28M* units @$6.00—each unit consists of one share and one 5-year warrant exercisable at $6.60:

http://finance.yahoo.com/news/opgen-announces-pricing-initial-public-123000795.html

OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company's products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company's lead product is the Acuitas MDRO Gene Test. Products in development include the Acuitas Lighthouse MDRO Management System and the Acuitas Resistome Test.

The warrants will trade under the ticker symbol, OPGNW.

*Assuming exercise of underwriter’s option.